Triple-Drug cocktail shows promise against CLL
NCT ID NCT02427451
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a combination of three drugs—obinutuzumab, ibrutinib, and venetoclax—for people with chronic lymphocytic leukemia (CLL) that has come back, not responded to treatment, or is newly diagnosed. The goal is to find the best dose and see how well the combination works. About 87 participants will receive the drugs to control the disease and reduce cancer cells to undetectable levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Obinutuzumab, ibrutinib, and venetoclax
What this could lead to
If successful, this combination could offer a more effective treatment option for CLL, potentially leading to longer remission without the need for continuous therapy.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants. The combination may cause significant side effects, and it is not yet known if it will work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States